The stock's fall snapped a four-day winning streak.

明尼阿波利斯 - Bio-Techne Corporation (NASDAQ: TECH) 再次在与Miltenyi Biotec的法律纠纷中取得胜利，科隆地区法院裁定支持这家生命科学公司。法院认定Miltenyi Biotec非法销售从Bio-Techne专有的R&D Systems品牌NKG2C/CD159c抗体反向工程而来的抗体。

This was the stock's fourth consecutive day of gains.

MINNEAPOLIS, Jan. 10, 2025 /PRNewswire/ -- Bio-Techne (NASDAQ: TECH), a global leader in life science tools and reagents, today announced the launch of new designer proteins engineered using ...

The Brooklyn organization, seeking new audiences and pushing boundaries, debuts Techne, four digital installations from the ...

Bio-Techne Corporation (NASDAQ: TECH) today announced that it prevailed on another claim that Miltenyi Biotec B.V. & Co. KG commercialized antibodies developed based on information obtained by reverse ...

IL-2 Heat Stable Agonist: Engineered with enhanced thermal stability and altered receptor affinity for improved biological activity, ideal for cellular therapy applications such as CAR T-cell or Tumor ...

Bio-Techne Corp. (TECH), a life sciences company, announced Tuesday that it has won a second claim of reverse engineering by Miltenyi ...

Bio-Techne (TECH) prevailed on another claim that Miltenyi Biotec KG commercialized antibodies developed based on information obtained by ...

(RTTNews) - Bio-Techne Corp. (TECH), a life sciences company, announced Tuesday that it has won a second claim of reverse engineering by Miltenyi Biotec B.V. & Co. KG, which may appeal the Court's ...

Bio-Techne Corporation (TECH), headquartered in Minneapolis, Minnesota, develops, manufactures, and sells life science ...